Inhibitex to Present at Two Upcoming Investor Conferences
October 29 2010 - 4:28PM
Business Wire
Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company
focused on developing products to treat and prevent serious
infectious diseases, announced that Russell H. Plumb, President and
Chief Executive Officer, is scheduled to present an overview of the
company and its pipeline of differentiated antiviral compounds at
the following two investor conferences in November:
- The Oppenheimer 21st Annual Healthcare
Conference on November 3, 2010 at 1:35 PM ET. The conference is
being held at the Waldorf-Astoria in New York City.
- Lazard Capital Markets 7th Annual
Healthcare Conference on November 17, 2010 at 10:00 AM ET. The
conference is being held at the St. Regis Hotel in New York
City.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to prevent
and treat serious infectious diseases. The Company’s pipeline
includes FV-100, which is in Phase II clinical development for the
treatment of shingles, and INX-189, a nucleotide polymerase
inhibitor in Phase 1 clinical development for the treatment of
chronic hepatitis C infections. The Company also has additional HCV
nucleotide polymerase inhibitors in preclinical development, and
has licensed the use of its proprietary MSCRAMM® protein platform
to Pfizer for the development of staphylococcal vaccines. For
additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024